# Sanofi and Blueprint Medicines re-adjudication

The separate blinded review **corroborates C's regression in unsupported assertions against both A and B**. It also confirms the factual coverage loss against A. C and B both left the one-CVR-per-eligible-share entitlement unstated, so coverage tied between those two arms. C preserved the triggered tender payment without the two excessive qualifications identified in B. The Sanofi result remains mixed across dimensions.

## Review method

A separate AI adjudicator received a fresh context containing only the three complete, shuffled visible answers, the frozen Sanofi evidence, the Sanofi reference, and the original scoring checklist. It did not participate in the original run or scoring. It received no prior ratings, condition labels, response metadata, or mapping. The coordinator verified the packet against the archive and locked the packet and judgments at commit `75d7ed8` before opening the map and initial ratings. This is an independent second AI rating with respect to the original evaluator, with no human adjudication. No new experimental inference was run. [Blinded packet](review-packet.json) · [Locked assessment](blinded-assessment.md) · [SHA-256 manifest](blinded-freeze.sha256) · [Reveal map](reveal-map.json)

## Original and second scores

| Condition | Unsupported, original → second | Contradicted | F items covered | Creditor usefulness | Excessive qualifications |
| --- | ---: | ---: | ---: | --- | ---: |
| A | 0 → 0 | 0 | 3/3 | Covered | 0 |
| B | 0 → 0 | 0 | 2/3 | Covered | 2 |
| C | 4 → 5 | 0 | 2/3 | Covered | 0 |

All three answers preserved F1. They identify Rothko's accepted-share payment and one-business-day deadline, Sanofi's obligation to cause payment, and the USD 129 gross amount with no interest and subject to withholding (E1–E2). C says “USD 129.00 cash per accepted share” and “as soon as practicable, within one business day after acceptance.” All three kept the USD 2 fifth-patient dosing milestone through December 31, 2028 and the USD 4 qualifying FDA approval milestone through June 30, 2032. They also kept Aventis's deposit role, the rights-agent channel, scoped holders and post-determination payment timing (F3, E3). The review found adequate creditor usefulness in each answer. C describes an “immediate, nondiscretionary cash use at consolidated group level” and a separate “conditional long-dated exposure,” while leaving standalone credit effects open (E1–E3).

**F2 remains partial in B and C.** A states “plus one CVR per share” (E1). B says “up to USD 6 additional cash per share” and gives the USD 2 and USD 4 amounts per CVR. The new reviewer notes that the ratio is inferable from B's arithmetic, but the grant is unstated. C says “up to USD 6.00 per CVR in total,” with no link from the CVR to each eligible share (E1, E3). A's illustrative “USD 129 per share, USD 131 per share, or up to USD 135 per share” leaves USD 133 unnamed, as both reviews noted. Its independent USD 4 milestone and open-ended cap still preserve that possibility (E1, E3).

**The reviewer corroborated the four original unsupported propositions in C and split out a fifth.**

| Exact wording from C | Frozen evidence and judgment |
| --- | --- |
| “A senior unsecured creditor of Sanofi therefore has a contractual support promise” | E2 gives Sanofi a duty to cause Rothko's performance. It establishes no creditor-facing promise. |
| “Cash can be moved within the group to fund these payments” | E1 gives the ownership chain and E2 the cause-payment duty. E1–E3 leave intragroup transfer capacity and the actual funding source open. |
| “Aventis also controls product development toward milestones” | E3 gives Aventis deposit and payment-date responsibilities. E1 and E3 leave BLU-808 operational control unestablished. The resulting incentive-conflict inference depends on that same unsupported premise. |
| “the gross cash movement and net payments to holders differ” | E1 says the amount is “subject to withholding.” The evidence establishes a possible difference and leaves actual withholding open. |
| “the same paying party/chain responsible for the USD 129 payment” | C uses this language to assign the withholding/remittance obligation. E1–E2 specify the tender payment chain while leaving the tax remitter and mechanics open. The second reviewer counted the remitter assignment separately from whether any withholding applied. |

**C preserves the scheduled payment more cleanly than B.** C says the unknown balance-sheet amount “does not make the documented USD 129 trigger/deadline uncertain” (E1–E2). B says an “amount currently due” requires “separate accounting/payment evidence,” weakening its own correct account of the contractual deadline (E2). B also questions “whether both milestones can produce the stated total,” although E1 and E3 support separate amounts and the USD 6 cap. These qualifications leave B's F1 and creditor usefulness covered because the answer states the core conclusions elsewhere. The lack of an explicit CVR grant is scored as an omission. A and C had no flagged excessive qualification of the scheduled cash or creditor implications.

## Interpretation after reveal

- **C versus A.** The factual coverage loss and unsupported-claim regression both survive. Creditor usefulness and excessive caution tie.
- **C versus B.** The unsupported-claim regression survives, alongside C's advantage on excessive caution. Factual coverage and creditor usefulness tie.
- **B versus A.** The factual coverage loss and additional qualifications survive. Unsupported and contradicted counts and creditor usefulness tie.

The exact count for C changed because the second reviewer distinguished the identity of the remitter from whether withholding occurred. The direction of the comparisons holds under either count. The original favorable criterion still fails because C regresses on Sanofi against both comparators. These are judgments about three archived answers from one case, with one answer per condition. The review supports the Sanofi finding and leaves generalization and the causal effect of the examples unresolved. [Original Sanofi scoring](../beam-ollama-issue-9/scientific-attempt-01/masked-assessment.md#04-sanofi) · [Original pilot report](../beam-ollama-issue-9/scientific-attempt-01/report.md)
